← Leaderboards
Esma S Yolcu
University Of Louisville
$2,168,034
Attributed
$4,383,315
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $761.1K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,383,315 · 5
By mechanism
U01$2,012,531 · 1
UG3$1,522,188 · 1
R21$399,068 · 1
R43$224,999 · 1
R41$224,529 · 1
Top collaborators
- Haval Shirwan7 shared
- Andres J Garcia5 shared
- Robert Ray Redfield1 shared
Most similar at University Of Louisville
Same institution · by research overlap
- Suzanne T Ildstad$11,948,900
- Xiao-An Fu$1,588,474
- Hui Shao$5,494,104
- Cheri Alicia Levinson$7,536,321
- Adam E Gaweda$2,491,950
Others in their field
Top investigators on “Failure”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$305,871,236
- Constance Ann Benson · University Of California, San Diego$187,132,366
- David M Nathan · Massachusetts Institute Of Technology$129,771,015
- John M Lachin · George Washington University$122,721,121
- Judith S Hochman · New York University School Of Medicine$119,832,568
- Wafaa M. El-Sadr · Columbia University Health Sciences$95,753,873
Research focus
FailureDesignHumanized MouseAntigensMouse ModelPreventPlayPathway InteractionsImmuneBindingCell TypeReceptorPre-Clinical ModelSignal TransductionInnovationAgonistSuccessAutoantigensApoptoticAffectApoptosisAllogenicFoxp3 GeneEfficacy Testing
Grant awards (11)
Developing a novel agonist of CD137 for cancer immunoprevention$761,094
UG3 · FY2025 · CA
Developing a novel agonist of CD137 for cancer immunoprevention$761,094
UG3 · FY2024 · CA
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$420,968
U01 · FY2021 · AI
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$413,601
U01 · FY2020 · AI
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$388,154
U01 · FY2019 · AI
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$388,154
U01 · FY2018 · AI
Exploiting activation-induced cell death as a means of inducing tolerance to kidney allografts$224,999
R43 · FY2018 · AI · contact PI
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts$401,654
U01 · FY2017 · AI
SA-FasL-engineered human islets as a novel product for the treatment of type 1 diabetes$224,529
R41 · FY2017 · DK · contact PI
Engineering Bone Marrow Cells for Immunotherapy$215,318
R21 · FY2006 · HL · contact PI
Engineering Bone Marrow Cells for Immunotherapy$183,750
R21 · FY2005 · HL